EPILEPSY THERAPIES & DIAGNOSTICS DEVELOPMENT XVII

(ETDD - formally AEDD)

 May 31st – June 2nd, 2023
JW Marriott Miami Turnberry Resort
19999 West Country Club Drive, Aventura Florida, 33180

Welcome to the website for the 17th conference on Epilepsy Therapies & Diagnostic Development (formally the Antiepileptic Drug & Device Symposium), held every two years and sponsored by the Epilepsy Study Consortium, Inc. in collaboration with the University of Pennsylvania and the Epilepsy Foundation.

If you have any questions about the conference, please contact Tracy DeVito [devito@epilepsyconsortium.org] or Bree DiVentura [diventura@epilepsyconsortium.org] at the Epilepsy Study Consortium.

Program

This is the seventeenth conference focusing on issues related to Epilepsy Therapies & Diagnostic Developments (ETDD) from preclinical discoveries through clinical evaluations. We are fortunate to have a robust epilepsy drug and device pipeline, fueled by excellent science and novel ideas.  We are entering an exciting era where therapies targeted at disease modification , rather than just anti-seizure treatment are emerging, and there is a focus on personalized treatments. There are also many treatments in the pipeline for orphan diseases. There is a burgeoning pipeline of wearable and implantable diagnostic devices. New therapeutic devices are also under development. New innovations in therapy and diagnostics  may face roadblocks such as complex regulatory requirements, increased payer expectations, and issues in data quality, but progress has been made. At each ETDD conference, we re-evaluate strategies to ensure continued advancement. There is always the opportunity to learn from the past as we move into the future. This symposium will bring together representatives from academia, industry, and the NIH, to review what has been learned and to discuss strategies to enhance epilepsy therapy and diagnostics development.

Click HERE (or on the program image) to download the 2023 program.

Registration - Conference & Hotel

Meeting Purpose

In an era where we have BROUGHT numerous new antiepileptic drugs to the marketplace, we need to be mindful of the unmet needs….

For more than three decades a group of individuals have been meeting on a biennial basis to discuss ways in which the process of bringing innovative therapies and devices to patients can be expedited. Participants include individuals from academia, from interested government agencies, as well as representatives from the pharmaceutical and device industries. The purpose of these meetings has been the exchange of ideas, discussion of roadblocks to therapeutic and diagnostic development, dialogue about regulatory strategies, and sharing of successful approaches. Over the years, discussions at this symposium have led to implementation of new trial designs, as well as new important analyses of trials that have already been performed. In addition, new regulatory pathways have been identified, particularly as related to approval of new antiepileptic drugs for monotherapy use. In addition, each meeting presents a pipeline of drugs and devices currently in development, and includes a Shark Tank competition, where novel innovations to improve the lives of people with epilepsy are presented.

Objectives